Immunohistochemical detection of c-fos and c-jun expression in osseous and cartilaginous tumours of the skeleton - PubMed

Immunohistochemical detection of c-fos and c-jun expression in osseous and cartilaginous tumours of the skeleton

A Franchi et al. Virchows Arch. 1998 Jun.

Abstract

The products of c-fos and c-jun proto-oncogenes form the heterodimeric complex AP-1 (activator protein 1), which play an important part in the control of bone cell proliferation and differentiation and in the development of bone tumours. We examined the expression of c-fos and c-jun in a series of 52 primary skeletal neoplasms, using an immunohistochemical method on formalin-fixed, paraffin-embedded sections. The expression of c-fos and c-jun was restricted to bone-forming lesions, while cartilaginous tumours were devoid of immunoreactivity. In benign osteoblastic lesions moderate c-fos and c-jun expression was found in 2 cases (18.1%). The highest levels of c-fos and c-jun expression were detected in high-grade central osteosarcomas (7 of 15 cases with moderate/diffuse expression) while 1 telangiectatic osteosarcoma, 2 low-grade central osteosarcomas, 1 low-grade periosteal osteosarcoma and 7 low-grade parosteal osteosarcomas were either negative or had low expression. The high-grade component of a dedifferentiated parosteal osteosarcoma showed diffuse immunoreactivity for both oncoproteins. Comparison of c-fos and c-jun expression by histological grade showed that high-grade osteosarcomas had a significantly higher expression of both oncoproteins than did low-grade osteosarcomas (P = 0.01, Fisher's exact test). Thus, c-fos and c-jun overexpression may be implicated in the development of high-grade osteosarcomas, but they appear to have little or no relevance for the development of low-grade osteosarcomas and cartilaginous skeletal neoplasms.

Similar articles

• Activation of the JNK-AP-1 signal transduction pathway is associated with pathogenesis and progression of human osteosarcomas.

  Papachristou DJ, Batistatou A, Sykiotis GP, Varakis I, Papavassiliou AG. Papachristou DJ, et al. Bone. 2003 Apr;32(4):364-71. doi: 10.1016/s8756-3282(03)00026-7. Bone. 2003. PMID: 12689679

• Expression of transforming growth factor beta isoforms in osteosarcoma variants: association of TGF beta 1 with high-grade osteosarcomas.

  Franchi A, Arganini L, Baroni G, Calzolari A, Capanna R, Campanacci D, Caldora P, Masi L, Brandi ML, Zampi G. Franchi A, et al. J Pathol. 1998 Jul;185(3):284-9. doi: 10.1002/(SICI)1096-9896(199807)185:3<284::AID-PATH94>3.0.CO;2-Z. J Pathol. 1998. PMID: 9771482

• Detection of c-fos expression in benign and malignant musculoskeletal lesions.

  Weisstein JS, Majeska RJ, Klein MJ, Einhorn TA. Weisstein JS, et al. J Orthop Res. 2001 May;19(3):339-45. doi: 10.1016/S0736-0266(00)90020-2. J Orthop Res. 2001. PMID: 11398843

• AP-1 (Fos/Jun) transcription factors in hematopoietic differentiation and apoptosis.

  Liebermann DA, Gregory B, Hoffman B. Liebermann DA, et al. Int J Oncol. 1998 Mar;12(3):685-700. doi: 10.3892/ijo.12.3.685. Int J Oncol. 1998. PMID: 9472112 Review.

• Osteogenic sarcomas of the hands: A case series with emphasis in its peculiarities and literature review.

  de la Guardia V, O'Meally AA, Gambarotti M, Spinnato P, Frisoni T, Cocchi S, Magagnoli G, Ibrahim T, Benini S, Pacheco M, Righi A. de la Guardia V, et al. Pathol Res Pract. 2023 Feb;242:154326. doi: 10.1016/j.prp.2023.154326. Epub 2023 Jan 20. Pathol Res Pract. 2023. PMID: 36716613 Review.

Cited by

• Chondrosarcomatous differentiation in diffuse-type gastric carcinoma.

  Villanacci V, Gambarotti M, Ubiali A, Cervi G, Pulcini G, De Cesare V, Bassotti G. Villanacci V, et al. Dig Dis Sci. 2006 Sep;51(9):1658-61. doi: 10.1007/s10620-005-9040-x. Epub 2006 Aug 22. Dig Dis Sci. 2006. PMID: 16927146 No abstract available.

• Genomic Analysis Does Not Support Malignant Transformation of Osteoblastoma to Osteosarcoma.

  Geller DS, Levine NL, Hoang BH, Yang R, Weiser D, Morris J, Gorlick R, Gill JB, Roth ME, Tingling J, Brohl AS. Geller DS, et al. JCO Precis Oncol. 2019 Sep 9;3:PO.19.00166. doi: 10.1200/PO.19.00166. eCollection 2019. JCO Precis Oncol. 2019. PMID: 32914027 Free PMC article. No abstract available.

• shRNA mediated knockdown of Nav1.7 in rat dorsal root ganglion attenuates pain following burn injury.

  Cai W, Cao J, Ren X, Qiao L, Chen X, Li M, Zang W. Cai W, et al. BMC Anesthesiol. 2016 Aug 11;16(1):59. doi: 10.1186/s12871-016-0215-0. BMC Anesthesiol. 2016. PMID: 27514860 Free PMC article.

• Identification of a 7-mRNA signature as a prognostic biomarker in pediatric osteosarcoma.

  Cui T, Guo J, Jin C. Cui T, et al. Transl Cancer Res. 2020 Nov;9(11):6733-6742. doi: 10.21037/tcr-20-2407. Transl Cancer Res. 2020. PMID: 35117283 Free PMC article.

• c-Fos induces chondrogenic tumor formation in immortalized human mesenchymal progenitor cells.

  Abarrategi A, Gambera S, Alfranca A, Rodriguez-Milla MA, Perez-Tavarez R, Rouault-Pierre K, Waclawiczek A, Chakravarty P, Mulero F, Trigueros C, Navarro S, Bonnet D, García-Castro J. Abarrategi A, et al. Sci Rep. 2018 Oct 23;8(1):15615. doi: 10.1038/s41598-018-33689-0. Sci Rep. 2018. PMID: 30353072 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Springer

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Molecular Biology Databases

  • Mouse Genome Informatics (MGI)

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal